Advertisement
Screener

FOXO TECHNOLOGIES INC. (FOXO) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

FOXO TECHNOLOGIES INC. Research and Development Expense

FOXO TECHNOLOGIES INC. (FOXO) reported Research and Development Expense of $23.70 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14

  • FOXO TECHNOLOGIES INC. research and development expense for the quarter ending 2026-06-30 was $23.70K, a 41.02% decline year-over-year.
  • FOXO TECHNOLOGIES INC. research and development expense for the quarter ending 2026-03-31 was $35.55K, a 18.50% increase year-over-year.
  • FOXO TECHNOLOGIES INC. research and development expense for the quarter ending 2025-12-31 was $35.22K.
  • FOXO TECHNOLOGIES INC. research and development expense for the quarter ending 2025-09-30 was $77.10K, a 75.99% increase year-over-year.
  • FOXO TECHNOLOGIES INC. research and development expense for fiscal 2025 was $182.50K, a 41.56% decline from fiscal 2024.
  • FOXO TECHNOLOGIES INC. research and development expense for fiscal 2024 was $312.27K, a 65.32% decline from fiscal 2023.
  • FOXO TECHNOLOGIES INC. research and development expense for fiscal 2023 was $900.43K, a 70.45% decline from fiscal 2022.
  • FOXO TECHNOLOGIES INC. research and development expense for fiscal 2022 was $3.05M, a 37.55% decline from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filed
2026-06-30$23.70K
10-Q · filed 2026-08-14
$59.25K
10-Q · filed 2026-08-14
$94.47K
derived: sum of 3 quarters · filed 2026-08-14
$171.56K
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$35.55K
10-Q · filed 2026-05-15
$70.77K
derived: sum of 2 quarters · filed 2026-05-15
$147.87K
derived: sum of 3 quarters · filed 2026-05-15
$188.05K
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31$35.22K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
$112.31K
derived: sum of 2 quarters · filed 2026-04-15
$152.50K
derived: sum of 3 quarters · filed 2026-08-14
$182.50K
10-K · filed 2026-04-15
2025-09-30$77.10K
10-Q · filed 2025-11-10
$117.28K
derived: sum of 2 quarters · filed 2026-08-14
$147.28K
10-Q · filed 2025-11-10
$147.28K
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30$40.18K
10-Q · filed 2026-08-14
$70.18K
10-Q · filed 2026-08-14
$70.18K
derived: sum of 3 quarters · filed 2026-08-14
$113.99K
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31$30.00K
10-Q · filed 2026-05-15
$30.00K
derived: sum of 2 quarters · filed 2026-05-15
$73.81K
derived: sum of 3 quarters · filed 2026-05-15
$176.91K
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
$43.81K
derived: sum of 2 quarters · filed 2026-04-15
$146.91K
derived: sum of 3 quarters · filed 2026-04-15
$312.27K
10-K · filed 2026-04-15
2024-09-30$43.81K
10-Q · filed 2025-11-10
$43.00K
10-Q · filed 2024-11-19
$146.91K
derived: sum of 2 quarters · filed 2025-11-10
$312.27K
10-Q · filed 2025-11-10
$312.00K
10-Q · filed 2024-11-19
$287.70K
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30$103.10K
10-Q · filed 2025-08-19
$104.00K
10-Q · filed 2024-08-19
$268.46K
10-Q · filed 2025-08-19
$269.00K
10-Q · filed 2024-08-19
$243.89K
derived: sum of 3 quarters · filed 2025-08-19
$526.89K
derived: sum of 4 quarters · filed 2025-08-19
2024-03-31$165.36K
10-Q/A · filed 2025-08-19
$165.00K
10-Q · filed 2024-06-28
$140.79K
derived: sum of 2 quarters · filed 2025-08-19
$423.79K
derived: sum of 3 quarters · filed 2025-08-19
$756.79K
derived: sum of 4 quarters · filed 2025-08-19
2023-12-31-$24.57K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15
$258.43K
derived: sum of 2 quarters · filed 2025-04-15
$591.43K
derived: sum of 3 quarters · filed 2025-04-15
$900.43K
10-K · filed 2025-04-15
$901.00K
10-K · filed 2024-06-06
2023-09-30$283.00K
10-Q · filed 2024-11-19
$616.00K
derived: sum of 2 quarters · filed 2024-11-19
$925.00K
10-Q · filed 2024-11-19
$1.81M
derived: sum of 4 quarters · filed 2024-11-19
2023-06-30$333.00K
10-Q · filed 2024-08-19
$642.00K
10-Q · filed 2024-08-19
$1.53M
derived: sum of 3 quarters · filed 2024-08-19
$2.09M
derived: sum of 4 quarters · filed 2024-08-19
2023-03-31$309.00K
10-Q · filed 2024-06-28
$1.20M
derived: sum of 2 quarters · filed 2024-06-28
$1.75M
derived: sum of 3 quarters · filed 2024-06-28
$2.75M
derived: sum of 4 quarters · filed 2024-06-28
2022-12-31$887.00K
derived: 10-K 12 month − 10-Q/A 9 month · filed 2024-06-06
$1.45M
derived: sum of 2 quarters · filed 2024-06-06
$2.45M
derived: sum of 3 quarters · filed 2024-06-06
$3.05M
10-K · filed 2024-06-06
2022-09-30$558.00K
10-Q/A · filed 2024-06-04
$1.56M
derived: sum of 2 quarters · filed 2024-06-04
$2.16M
10-Q/A · filed 2024-06-04
$2.72M
derived: sum of 4 quarters · filed 2024-06-04
2022-06-30$1.00M
10-Q · filed 2023-08-10
$1.60M
10-Q · filed 2023-08-10
$2.16M
derived: sum of 3 quarters · filed 2023-08-10
$3.83M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$601.00K
10-Q · filed 2023-05-11
$1.16M
derived: sum of 2 quarters · filed 2023-05-11
$2.82M
derived: sum of 3 quarters · filed 2023-05-11
2021-12-31$558.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31
$2.22M
derived: sum of 2 quarters · filed 2023-03-31
$4.88M
10-K · filed 2023-03-31
2021-09-30$1.67M
10-Q · filed 2022-11-21
$4.32M
10-Q · filed 2022-11-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
iSpecimen Inc. (ISPC)United States$0.003B
OneMedNet Corp (ONMD)$0.042B
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
NRC HEALTH (NRC)United States$0.450B42.50
OmniAb, Inc. (OABI)United States$0.698B-8.05
Absci Corp (ABSI)United States$1.775B-14.92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14